Clinical trials: Neoplasm Circulating Cells
Circulating Tumor Cell, Oropharyngeal Cancer
Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)
Head and neck cancers (HNSCC) are primarily squamous cell cancers represented by tumors of the upper aerodigestive tract. Locally advanced stages (stages III and IV) account for 50 to 70% of all presentations.
- Trial name
- CTCO (NCT04696744)
- Testing
- CTC detection
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Lung Cancer, NSCLC
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy.
- Trial name
- NCT04367311
- Testing
- Atezolizumab, Docetaxel, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nasser Hanna
Lung Cancer, Nonsmall Cell
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
This study aims to incorporate circulating tumor DNA (ctDNA)-minimal residual disease (MRD) to personalize the administration of consolidation toripalimab therapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC) after…
- Trial name
- CONTINUE (NCT06426511)
- Testing
- Toripalimab+Chemotherapy, Toripalimab+Chemotherapy followed by consolidation toripalimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Melanoma, Skin Cancer
Circulating Tumor DNA in Melanoma Patients
The aim of this prospective clinical study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma.
- Trial name
- ctDNA (NCT07422805)
- Testing
- Blood Sampling for ctDNA Analysis
- Where
- Slovenia
- Volunteers
- 176 people
- Sponsor
- Institute of Oncology Ljubljana
Pancreatic Ductal Adenocarcinoma (PDAC), Circulating Tumor Cells (CTCs)
Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy
The aim of this study was to evaluate the clinical utility of mesenchymal CTC ratio dynamics as a real-time biomarker for PDAC patients with neoadjuvant therapy.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Circulating Tumor Cells (CTCs), Neoadjuvant Therapy
- Trial name
- NCT07329920
- Testing
- surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Guo ShiWei
Neoplasms, Cancer
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early.
- Trial name
- NCT03085888
- Where
- 35 sites in United States
- Volunteers
- 99,481 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Thoracic Cancer, Ovarian Cancer
Project CADENCE (CAncer Detected Early caN be CurEd)
With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be…
- Conditions
- Thoracic Cancer, Ovarian Cancer, Liver Cancer, Prostate Cancer
- Trial name
- CADENCE (NCT05633342)
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiRXES Pte Ltd
Circulating Tumor Cell
Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer
Through the screening of CTCs in patients with suspected liver cancer and liver tumor resection or liver transplantation, the number of CTCs in the blood of liver cancer patients before and after surgery is monitored, and the…
- Trial name
- NCT04688606
- Testing
- Circulating tumor cell capture technology
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Colorectal Cancer
Colonic Stent and Tumor Cell Dissemination
This study aims to examine the hypothesis of tumor cell dissemination after colonic stenting for obstructing colorectal cancer by measuring the level of plasma circulating tumor cell before and after the procedure of successful…
- Trial name
- NCT01628328
- Volunteers
- 40 people
- Sponsor
- The University of Hong Kong
Non Small Cell Lung Cancer, Chronic Obstructive Pulmonary Disease
Study of Use of CTC in NSCLC
The purpose of this study is to assess whether the detection of circulating tumor cells (CTC) could be used as a tool to earlier diagnose, more accurately predict treatment response / failure and predict overall survival in…
- Trial name
- NCT01990651
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Carcinoma, Non-Small-Cell Lung
Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer
Genetic rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene result in the creation of a variety of oncogenic fusion proteins that drive malignancy in a subset of non-small cell lung cancers (NSCLC) patients.
- Trial name
- NCT02718651
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- University of Aarhus
Non Small Cell Lung Cancer
Evaluation of a Novel Microfluidic Device to Purify Metastatic Lung Cancer Patients CTC (Circulating Tumoral Cells)
Currents strategies for cancer diagnosis consist of the extraction of a solid tissue from the affected area. This sample enables the study of specific biomarkers and the genetic nature of the tumor.
- Trial name
- LUTON (NCT04957602)
- Testing
- Blood collection
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Hospices Civils de Lyon
Advanced Lung Non-Small Cell Carcinoma
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)
- Trial name
- CR1STAL (NCT05198154)
- Testing
- ctDNA detection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fang Wu
Locally Advanced Breast Cancer, Circulating Tumor Cell
CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. The purpose of this clinical trial is to evaluate the predictive value of CTC in neoadjuvant chemotherapy among locally…
- Trial name
- CTCNeoBC (NCT03732339)
- Testing
- GILUPI CellCollector®
- Where
- China
- Volunteers
- 29 people
- Sponsor
- RenJi Hospital
Metastatic Breast Cancer, Breast Cancer
Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients
The objective of the registry study is to demonstrate the clinical utility of the CELLSEARCH® CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in the United States.
- Trial name
- NCT02111031
- Where
- 2 sites in United States
- Sponsor
- Janssen Diagnostics, LLC
Thyroid Nodule, Diagnoses Disease
Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells)
Thyroid nodule patients with suggestion of fine needle aspiration biopsy (FNAB) offered by ultrasound are enrolled in the study. CTCs tested by Optimizing method and FNAB will be performed simultaneously.
- Trial name
- CTCs (NCT03772496)
- Testing
- circulating tumor cells test, Fine needle aspiration biopsy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Brain Tumor, Primary, Brain Tumor - Metastatic
Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors
The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the…
- Trial name
- NCT05831631
- Testing
- Circulating leukocytes immunophenotype, Tumor sampling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Pietro Mortini, MD, Prof.
Multiple Myeloma
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells
To evaluate the overall response rate, safety, and the 12-cycle clearance rate of circulating plasma cells (CPCs) in patients with newly diagnosed transplant-ineligible multiple myeloma stratified as high-risk based on…
- Trial name
- NCT07732712
- Testing
- Isatuximab, VRD
- Volunteers
- 15 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer
Microlyvaq™ is a first-line, non-randomized, two-arm clinical trial in advanced non-small cell lung cancer (NSCLC). In both arms, patients receive a personalized multi-epitope vaccine (Microlyvaq™) on top of standard-of-care…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- Microlyvaq™ (NCT07285434)
- Testing
- Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic)
- Where
- Greece
- Volunteers
- 90 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Nonsmall Cell Lung Cancer
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
The purpose of this study is to determine whether it is feasible and safe to give research participants investigational treatment with durvalumab and tremelimumab after they have completed standard treatment for NSCLC and once…
- Trial name
- NCT04625699
- Testing
- Durvalumab, Tremelimumab
- Sponsor
- Catherine Shu